NOT FOR DISTRIBUTION
Header cover image

Market Cap

CHF5.6b

Last Updated

2021/04/09 17:03 UTC

Data Sources

Company Financials +

Executive Summary

Bachem Holding AG, a technology-based biochemicals company, provides services to the pharmaceutical and biotechnology industries primarily in Switzerland, the United States, Germany, Ireland, the United Kingdom, Austria, Japan, and internationally. More Details

Rewards

Earnings are forecast to grow 21.05% per year

Earnings have grown 15.4% per year over the past 5 years

Risk Analysis

No risks detected for BANB from our risk checks.


Snowflake Analysis

High growth potential with excellent balance sheet.

Share Price & News

How has Bachem Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BANB is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: BANB's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

2.4%

BANB

2.0%

CH Life Sciences

0.8%

CH Market


1 Year Return

108.7%

BANB

64.7%

CH Life Sciences

21.0%

CH Market

Return vs Industry: BANB exceeded the Swiss Life Sciences industry which returned 64.7% over the past year.

Return vs Market: BANB exceeded the Swiss Market which returned 21% over the past year.


Shareholder returns

BANBIndustryMarket
7 Day2.4%2.0%0.8%
30 Day22.5%6.5%3.3%
90 Day5.4%7.5%5.3%
1 Year111.4%108.7%65.4%64.7%24.7%21.0%
3 Year248.3%228.8%164.4%158.5%35.0%19.0%
5 Year629.1%550.9%288.8%263.5%60.7%31.6%

Long-Term Price Volatility Vs. Market

How volatile is Bachem Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bachem Holding undervalued compared to its fair value and its price relative to the market?

75.22x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BANB (CHF419.5) is trading above our estimate of fair value (CHF124.36)

Significantly Below Fair Value: BANB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BANB is poor value based on its PE Ratio (75.2x) compared to the XE Life Sciences industry average (52.2x).

PE vs Market: BANB is poor value based on its PE Ratio (75.2x) compared to the Swiss market (24.9x).


Price to Earnings Growth Ratio

PEG Ratio: BANB is poor value based on its PEG Ratio (3.6x)


Price to Book Ratio

PB vs Industry: BANB is overvalued based on its PB Ratio (12.3x) compared to the XE Life Sciences industry average (5.9x).


Future Growth

How is Bachem Holding forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

21.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BANB's forecast earnings growth (21% per year) is above the savings rate (-0.3%).

Earnings vs Market: BANB's earnings (21% per year) are forecast to grow faster than the Swiss market (13.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BANB's revenue (15.1% per year) is forecast to grow faster than the Swiss market (4.5% per year).

High Growth Revenue: BANB's revenue (15.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BANB's Return on Equity is forecast to be high in 3 years time (24.9%)


Past Performance

How has Bachem Holding performed over the past 5 years?

15.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BANB has high quality earnings.

Growing Profit Margin: BANB's current net profit margins (19.4%) are higher than last year (17.3%).


Past Earnings Growth Analysis

Earnings Trend: BANB's earnings have grown by 15.4% per year over the past 5 years.

Accelerating Growth: BANB's earnings growth over the past year (43.9%) exceeds its 5-year average (15.4% per year).

Earnings vs Industry: BANB earnings growth over the past year (43.9%) underperformed the Life Sciences industry 43.9%.


Return on Equity

High ROE: BANB's Return on Equity (16.4%) is considered low.


Financial Health

How is Bachem Holding's financial position?


Financial Position Analysis

Short Term Liabilities: BANB's short term assets (CHF352.5M) exceed its short term liabilities (CHF137.5M).

Long Term Liabilities: BANB's short term assets (CHF352.5M) exceed its long term liabilities (CHF97.7M).


Debt to Equity History and Analysis

Debt Level: BANB's debt to equity ratio (22.6%) is considered satisfactory.

Reducing Debt: BANB's debt to equity ratio has increased from 5% to 22.6% over the past 5 years.

Debt Coverage: BANB's debt is well covered by operating cash flow (107.2%).

Interest Coverage: BANB's interest payments on its debt are well covered by EBIT (264.8x coverage).


Balance Sheet


Dividend

What is Bachem Holding current dividend yield, its reliability and sustainability?

0.77%

Current Dividend Yield


Upcoming Dividend Payment

TodayApr 10 2021Ex Dividend DateApr 30 2021Dividend Pay DateMay 04 20214 days from Ex DividendBuy in the next 19 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: BANB's dividend (0.77%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.51%).

High Dividend: BANB's dividend (0.77%) is low compared to the top 25% of dividend payers in the Swiss market (3.49%).


Stability and Growth of Payments

Stable Dividend: BANB is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.

Growing Dividend: BANB is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: BANB is not paying a notable dividend for the Swiss market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BANB's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Thomas Meier (52 yo)

1.25yrs

Tenure

CHF589,000

Compensation

Mr. Thomas Meier has been Chief Executive Officer of Bachem Holding AG since 2020. Mr. Meier served as Chief Operations Officer at Bachem Group since January 1, 2019 until 2020. He joined Bachem AG in 1993...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD636.08K) is below average for companies of similar size in the Swiss market ($USD2.08M).

Compensation vs Earnings: Insufficient data to compare Thomas's compensation with company performance.


Leadership Team

Experienced Management: BANB's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

Experienced Board: BANB's board of directors are considered experienced (8.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bachem Holding AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bachem Holding AG
  • Ticker: BANB
  • Exchange: SWX
  • Founded: 1971
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF5.555b
  • Shares outstanding: 13.73m
  • Website: https://www.bachem.com

Number of Employees


Location

  • Bachem Holding AG
  • Hauptstrasse 144
  • Bubendorf
  • Basel-Landschaft
  • 4416
  • Switzerland

Listings


Biography

Bachem Holding AG, a technology-based biochemicals company, provides services to the pharmaceutical and biotechnology industries primarily in Switzerland, the United States, Germany, Ireland, the United Ki...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/09 17:03
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.